Clinical Trials

16 enrolled

Lymphoma, T-Cell, Cutaneous

NCT01638533 2025-02-07

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckLymphoidNETOther hematologic neoplasmSarcomaThoracic

37 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Glioma, Lung Neoplasms, Lymphoma, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Neuroendocrine Tumors, Hematologic Neoplasms

NCT04774068 2025-01-17

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

5 enrolled

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT01755975 2024-11-07

Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

DermatologicLymphoidOther hematologic neoplasm

49 enrolled 15 charts

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT01998035 2024-08-22

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

Phase 1/2 Terminated

58 enrolled 11 charts

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03703375 2024-07-08

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Phase 3 Active not recruiting

93 enrolled 19 charts

Lymphoma, Lymphoma, T-Cell

NCT02232516 2024-04-10

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

Phase 2 Unknown

30 enrolled 17 charts

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

NCT02341014 2024-04-04

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

27 enrolled 13 charts

Lymphoma, Recurrence, Lymphoma, T-Cell

NCT00020202 2024-03-04

FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Genetic Diseases, Inborn, Small Cell Lung Carcinoma

NCT03742921 2023-12-06

ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

Completed

150 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT03534180 2023-10-19

Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma

12 enrolled 8 charts

Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT00104884 2023-06-28

FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Phase 2 Terminated

4 enrolled 4 charts

Dermatologic

Melanoma

NCT01796002 2023-01-10

Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Phase 3 Completed

421 enrolled

Lymphoma, T-Cell, Peripheral

NCT01947140 2022-11-23

PDX+Romi

DermatologicLymphoidOther hematologic neoplasmPlasma cell

57 enrolled

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04639843 2022-11-04

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT03770000 2022-10-28

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

33 enrolled 13 charts

Lymphoma, T-Cell

NCT03141203 2022-05-18

RomiCar

50 enrolled

Lymphoma, T-Cell, Peripheral

NCT03161223 2022-03-31

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

Phase 1/2 Recruiting

148 enrolled

Lymphoma, T-Cell

NCT00084682 2021-03-05

Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

14 enrolled 6 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01302808 2021-01-20

Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

17 enrolled 12 charts

Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion, Malignant

NCT02181218 2020-11-17

Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

24 enrolled

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT04233697 2020-08-13

Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma

Phase 1 Withdrawn

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell

NCT01902225 2020-06-09

Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma

24 enrolled

Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT01742793 2020-03-04

RID

Phase 1 Terminated

12 enrolled

LymphoidPlasma cell

Hodgkin Disease, Multiple Myeloma, Lymphoma, T-Cell

NCT00426764 2020-02-11

A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma

131 enrolled 16 charts

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT01445340 2019-12-17

Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma

Phase 1 Terminated

6 enrolled

Mycosis Fungoides, Neoplasms, Lymphoma, T-Cell, Cutaneous

NCT00048334 2019-12-12

Depsipeptide to Treat Thyroid and Other Advanced Cancers

28 enrolled

Tumor-Agnostic

Neoplasms

NCT00765102 2019-11-25

Trial of Romidepsin and Bortezomib for Multiple Myeloma

Phase 2 Terminated

32 enrolled 14 charts

Plasma cell

Multiple Myeloma

NCT01324310 2019-11-25

Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

LymphoidOther hematologic neoplasm

15 enrolled 21 charts

Lymphoma, Hematologic Neoplasms

NCT01324323 2019-11-25

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

LymphoidOther hematologic neoplasm

14 enrolled 21 charts

Lymphoma, Hematologic Neoplasms

NCT01353664 2019-11-25

A Rollover Study for Patients Who Participated in Other Romidepsin Protocols

19 enrolled 12 charts

Lymphoma, Neoplasms

NCT00106301 2019-11-18

Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228

2 enrolled

Genitourinary

Carcinoma, Renal Cell, Prostatic Neoplasms

NCT00106418 2019-11-18

A Research Study for Patients With Prostate Cancer

35 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00106431 2019-10-30

A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)

102 enrolled 15 charts

Lymphoma, T-Cell, Cutaneous

NCT00379639 2019-10-30

A Study of Romidepsin (Depsipeptide) in Combination With Gemcitabine in Patients With Pancreatic and Other Advanced Solid Tumors

36 enrolled 17 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00106613 2019-10-18

A Research Study for Patients With Metastatic Renal Cell Carcinoma